Acute Lymphoblastic Leukemia, in Relapse Clinical Trial
Official title:
Ponatinib for the Management of Minimal Residual Disease (MRD) and Hematologic Relapse in Adult Ph+ Acute Lymphoblastic Leukemia (Ph+ ALL) Patients
NCT number | NCT04475731 |
Other study ID # | ALL2620 |
Secondary ID | |
Status | Recruiting |
Phase | Phase 2 |
First received | |
Last updated | |
Start date | May 4, 2021 |
Est. completion date | November 2024 |
This is a phase II interventional trial to evaluate if the use of ponatinib, with or without chemotherapy, can induce a molecular remission in MRD-positive patients, in patients in hematologic and extra-hematologic relapse and in the few patients who never achieved an hematologic remission after whatever prior treatment.
Status | Recruiting |
Enrollment | 67 |
Est. completion date | November 2024 |
Est. primary completion date | November 2024 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: 1. Ph+ ALL patients with evidence of MRD disease or in hematologic and extra-hematologic relapse/refractoriness after any previous treatment, will be considered eligible to enter the study. 2. Age =18 years old with no upper age limit. 3. Adequate hepatic function as defined by the following criteria: - total serum bilirubin =1.5 x upper limit of normal (ULN), unless due to Gilbert's syndrome - alanine aminotransferase (ALT) =2.5 × ULN - aspartate aminotransferase (AST) =2.5 × ULN. 4. Adequate pancreatic function as defined by the following criterion: - serum lipase and amylase =1.5 × ULN. 5. For females of childbearing potential, a negative pregnancy test must be documented prior to enrollment. 6. Female and male patients who are fertile must agree to use an effective form of contraception with their sexual partners from enrollment through 4 months after the end of treatment. 7. Signed written informed consent according to ICH/EU/GCP and national local laws. Exclusion Criteria: 1. WHO performance status = 50% (Karnofsky) or = 3 (ECOG). 2. Uncontrolled active HBV or HCV hepatitis, or AST/ALT = 2.5 x ULN and bilirubine = 1.5 x ULN not due to the disease. 3. History of acute pancreatitis within 1 year of study or history of chronic pancreatitis. 4. History of alcohol abuse. 5. Ongoing or active uncontrolled infections. 6. Uncontrolled hypertriglyceridemia (triglycerides >450 mg/dL). 7. Clinically significant, uncontrolled or active cardiovascular disease, specifically including, but not restricted to: - any history of myocardial infarction, stroke, or revascularization - unstable angina or transient ischemic attack within 6 months prior to enrollment - congestive heart failure within 6 months prior to enrollment, or left ventricular ejection fraction (LVEF) less than lower limit of normal per local institutional standards within 6 months prior to enrollment - history of clinically significant (as determined by the treating physician) atrial arrhythmia - any history of ventricular arrhythmia - any history of venous thromboembolism including deep venous thrombosis or pulmonary embolism - uncontrolled hypertension (diastolic blood pressure >90 mm Hg; systolic >140 mm Hg). Patients with hypertension should be under treatment on study entry to effect blood pressure control. 8. Taking medications that are known to be associated with Torsades de Pointes. 9. Taking any medications or herbal supplements that are known to be strong inhibitors of CYP3A4 within at least 14 days before the first dose of ponatinib. 10. Creatinine level >2.5mg/dl or glomerular filtration rate (GFR) <20 ml/min or proteinuria >3.5 g/day. 11. Patients who are currently receiving treatment with any of the medications listed in Appendix E if the medications cannot be either discontinued or switched to a different medication prior to starting study drug. The medications listed in Appendix E have the potential to prolong QT. |
Country | Name | City | State |
---|---|---|---|
Italy | Aou Ospedali Riuniti "Umberto I - G.M. Lancisi - G. Salesi"- Ancona - Sod Clinica Ematologica | Ancona | |
Italy | Area Vasta N. 5 Ascoli Piceno - S. Benedetto Del Tronto, Presidio Ospedaliero Av5 Osp. Gen. Prov.Le "C.G.Mazzoni" - Uoc Ematologia | Ascoli Piceno | |
Italy | Ao Di Rilievo Nazionale E Di Alta Specialità "San Giuseppe Moscati" - Avellino - Uoc Ematologia Con Unità Di Trapianto | Avellino | |
Italy | Aou Consorziale Policlinico - Bari - Uo Ematologia Con Trapianto | Bari | |
Italy | Asst Papa Giovanni Xxiii - Ospedale Di Bergamo - Sc Ematologia | Bergamo | |
Italy | Aou Di Bologna - Policlinico S. Orsola-Malpighi - Uoc Ematologia | Bologna | |
Italy | Asst Degli Spedali Civili Di Brescia - Uo Ematologia | Brescia | |
Italy | Aso S. Croce E Carle - Cuneo - Sc Ematologia | Cuneo | |
Italy | Aou Careggi - Firenze - Sod Ematologia | Firenze | |
Italy | Aou Policlinico "G. Martino" - Messina - Uoc Ematologia | Messina | |
Italy | Aulss 3 Serenissima, Ospedale Dell'Angelo - Mestre - Uo Ematologia | Mestre | |
Italy | Asst Grande Ospedale Metropolitano Niguarda - Milano - Sc Ematologia | Milano | |
Italy | Irccs Ospedale S. Raffaele - Milano - Uo Oncoematologia | Milano | |
Italy | Aou Federico Ii - Napoli - Uoc Ematologia | Napoli | |
Italy | Ao Di Perugia, Ospedale S. Maria Della Misericordia - Ematologia E Trapianto Midollo Osseo | Perugia | |
Italy | Ao Ospedali Riuniti Marche Nord - Ospedale San Salvatore - Pesaro - Uoc Ematologia E Centro Trapianti | Pesaro | |
Italy | Università Degli Studi Di Roma "Sapienza" - Dipartimento Di Medicina Traslazionale E Di Precisione - U.O.C. Ematologia | Roma | |
Italy | Aou "San Giovanni Di Dio E Ruggi D'Aragona" - Salerno - Uoc Ematologia E Trapianti Di Cellule Staminali Emopoietiche | Salerno | |
Italy | Ente Ecclesiastico Casa Sollievo Della Sofferenza - San Giovanni Rotondo - Ematologia | San Giovanni Rotondo | |
Italy | Aou Senese - Uoc Ematologia E Trapianti | Siena | |
Italy | Aou Città Della Salute E Della Scienza, Ospedale S. Giovanni Battista Molinette - Torino - Sc Ematologia 2 | Torino | |
Italy | Aou Integrata Di Verona, Policlinico G.B. Rossi - Uoc Ematologia | Verona |
Lead Sponsor | Collaborator |
---|---|
Gruppo Italiano Malattie EMatologiche dell'Adulto |
Italy,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | MRD negativity/reduction rate | Rate of patients who achieve a MRD negativity/MRD reduction following treatment with either Ponatinib alone or in combination with systemic chemotherapy | After 3 months of treatment | |
Secondary | Duration of CMR | Duration of the CMR status after 3 months of ponatinib treatment | at 24 months | |
Secondary | Hematologic remission rate | The achievement of an hematologic remission in patients treated for an hematologic and extra-hematoloigc relapse and for a refractory disease. | at 24 months | |
Secondary | Best molecular response | Best molecular response achieved during the follow-up | at 24 months | |
Secondary | Rate of AE/SAEs | Safety profile in terms of incidence of grade >3 CTC-NCI side effects and toxicities (AE/SAEs). | at 24 months | |
Secondary | Mutational analysis | Mutational analysis in terms of occurrence, type and number of BCR-ABL1 kinase domain mutations. | at 24 months | |
Secondary | Correlation between biological and MRD parameters | Correlation between the achievement and duration of CMR (or MRD reduction) with the type of fusion protein (e.g. p190 or p210) and the potential occurrence of mutations, as well as with additional genomic lesions. | at 24 months | |
Secondary | Disease free survival | Time interval between the achievement of CHR after three months of ponatinib and hematologic relapse of the disease or death in CHR; patients still alive, in CHR. | 24 months | |
Secondary | Overall survival | Time interval between treatment start and death for any cause. | 24 months | |
Secondary | Cumulative incidence of relapse | Time interval between achievement of CHR after three months of ponatinib until the date of first hematologic relapse of the disease. | 24 months | |
Secondary | Role of hematological profile on survival outcome | Identification of hematological profile on survival outcome | at 24 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05066958 -
Ex-vivo Primed Memory Donor Lymphocyte Infusion to Boost Anti-viral Immunity After T-cell Depleted HSCT
|
Phase 1/Phase 2 | |
Completed |
NCT04224571 -
CCCG Relapsed Acute Lymphoblastic Leukemia 2017 Study in Children
|
Phase 2 | |
Recruiting |
NCT04888442 -
Phase I Study of pCAR-19B in the Treatment of Adult CD19-positive Relapsed/Refractory B-ALL
|
Phase 1 | |
Recruiting |
NCT05809284 -
Determining the Mechanisms of Loss of CAR T Cell Persistence
|
||
Recruiting |
NCT04049383 -
CAR-20/19-T Cells in Patients With Relapsed/Refractory B Cell ALL
|
Phase 1 | |
Not yet recruiting |
NCT05745714 -
HEM-iSMART-C: Ruxolitinib + Venetoclax + Dexamethasone + Cyclophosphamide and Cytarabine in Pediatric Patients With Relapsed or Refractory Hematological Malignancies
|
Phase 1/Phase 2 | |
Withdrawn |
NCT05740449 -
HEM-iSMART-A: Decitabine / Venetoclax and Navitoclax in Pediatric Patients With Relapsed or Refractory Hematological Malignancies
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT06213636 -
Fourth-gen CAR T Cells Targeting CD19/CD22 for Highly Resistant B-cell Lymphoma/Leukemia (PMBCL/CNS-BCL).
|
Phase 1/Phase 2 | |
Recruiting |
NCT04603872 -
CAR-T Cells Combined With Dasatinib for Patients With Relapsed and/or Refractory B-cell Hematological Malignancies
|
Early Phase 1 | |
Recruiting |
NCT06445803 -
CD19/CD22 CAR-T Cells in Adults With R/R ALL or NHL
|
Phase 1 | |
Recruiting |
NCT03957915 -
Study of Escalating Doses of INA03 Administered Intravenously as Single Agent in Adult Patients With Relapse/Refractory Acute Leukemia
|
Early Phase 1 | |
Terminated |
NCT03705507 -
International Trial of Selumetinib in Combination With Dexamethasone for the Treatment of Acute Lymphoblastic Leukaemia
|
Phase 1/Phase 2 | |
Recruiting |
NCT04340167 -
Study of Anti-CD22 CAR-T Cells Treating Leukemia Children
|
Phase 2 | |
Recruiting |
NCT04325841 -
Phase II Study of Anti-CD19 CAR-T Cells Treating Leukemia Children
|
Phase 2 | |
Recruiting |
NCT04605666 -
CD19-CAR-T2 Cells for CD19 Positive Acute Lymphoblastic Leukemia
|
Phase 2 | |
Active, not recruiting |
NCT04340154 -
Study of Sequential CAR-T Cell Treating Leukemia Children
|
Phase 2 | |
Recruiting |
NCT05292664 -
Venetoclax Basket Trial for High Risk Hematologic Malignancies
|
Phase 1 | |
Recruiting |
NCT06316427 -
Autologous and Donor-derived CD7 CAR-T Therapy in Refractory or Relapsed T-cell Acute Lymphoblastic Leukemia/Lymphoma
|
Phase 1/Phase 2 | |
Recruiting |
NCT05310591 -
Combination of an Anti-PD1 Antibody With Tisagenlecleucel Reinfusion in Children, Adolescents and Young Adults With Acute Lymphoblastic Leukemia After Loss of Persistence
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT05705570 -
A Phase I Clinical Trial Using Genetically Engineered Autologous T Cells to Express Chimeric Antigen Receptor (CAR) for Treatment of Patients With Refractory or Relapsed CD19-positive B Lymphoid Malignancies
|
Phase 1 |